Switchable CAR Segmentation for Tumor Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional chimeric antigen receptor (CAR) technology faces challenges such as uncontrolled immune responses, severe side effects, tumor escape variants, and limited retargeting capabilities, restricting its application due to safety issues and the risk of off-target toxicity.
Innovation Solution
A switchable chimeric antigen receptor (CAR) design that separates antigen recognition and activating domains into two separate units, using a universal binding domain and a targeting module to allow for reversible activation and reduced exhaustion, featuring a tag or tag-binding domain, an extracellular hinge and transmembrane domain, and multiple intracellular signaling domains for enhanced specificity and control.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional CAR technology is used to activate immune cells, then tumor cell killing activity is improved, but off-target toxicity and severe side effects occur
Solution Approach 1:
The CAR system is segmented into two independent components: a universal switchable CAR expressed on immune cells and a separate targeting module (antibody) that binds to both the CAR and target antigens. This segmentation allows the immune cells to be prepared in advance without committing to a specific target, and the targeting module can be selectively administered to control which targets are attacked, thereby reducing off-target toxicity while maintaining tumor cell killing activity.
Solution Approach 2:
The targeting module acts as an intermediary that bridges the universal CAR on immune cells and the specific target antigens. By introducing this intermediate component, the system gains controlled specificity - the CAR itself remains universal and non-specific, but the targeting module provides the necessary specificity to direct immune cells to tumor cells while avoiding normal cells, thus resolving the contradiction between activity and toxicity.
2Reliability
If CAR T cells are continuously activated to maintain therapeutic effect, then tumor control is improved, but T cell exhaustion occurs
Solution Approach 1:
The switchable CAR system enables periodic rather than continuous activation of T cells. The targeting module can be administered in cycles, allowing T cells to be activated when needed for tumor control and then rested when the targeting module is cleared or withheld. This periodic activation pattern maintains tumor control effectiveness while preventing T cell exhaustion, thereby extending the duration of T cell functionality.
3Ease of manufacture
If conventional CAR design with single antigen specificity is used, then manufacturing simplicity is maintained, but tumor escape variants develop
Solution Approach 1:
The universal CAR design provides multi-functionality by enabling the same CAR construct to target multiple different antigens through exchange of targeting modules. Instead of manufacturing different CARs for different targets, a single universal CAR can be paired with various targeting modules against different tumor antigens (e.g., HER2, CEA, EGFR). This approach maintains manufacturing simplicity while protecting against tumor escape variants by enabling easy switching between targets if resistance develops.
4Adaptability or versatility
If switchable CAR with separate targeting module is used, then retargeting flexibility and control are improved, but system complexity increases
Solution Approach 1:
The system is segmented into standardized, modular components with well-defined interfaces. The universal CAR contains a standardized tag or tag-binding domain, while targeting modules contain complementary tag-binding domains or tags. This segmentation creates interchangeable modules that can be easily combined, providing retargeting flexibility without proportionally increasing overall system complexity. The modular architecture allows complex functionality to be achieved through simple combinations of standardized parts.
Data Source
Figure 1
Figure 2~3
Figure 4A~4D
AI summary
The present invention relates to a switchable chimeric antigen receptor (CAR) comprising a tag or tag-binding domain, which is capable of binding a tag-binding domain or tag of a targeting module, wherein the targeting module comprises a target cell-binding domain. The invention also relates to a nucleic acid, vector or cell comprising a nucleotide sequence encoding the switchable CAR, a pharmaceutical composition comprising a nucleic acid, vector or cell comprising a nucleotide sequence encoding the switchable CAR, a kit and the use as a medicament, in particular for use in the treatment of cancer, infectious disease or autoimmune disease.